Quest diagnostics reports fourth quarter and full year 2022 financial results; provides guidance for full year 2023

Fourth quarter revenues of $2.33 billion, down 15.0% from 2021 fourth quarter reported diluted earnings per share ("eps") of $0.87, down 72.1% from 2021; and adjusted diluted eps of $1.98, down 40.5% from 2021 fourth quarter base business revenues of $2.15 billion, up 6.3% from 2021 fourth quarter covid-19 testing revenues of $184 million, down 74.6% from 2021 full year revenues of $9.88 billion, down 8.4% from 2021 full year reported diluted eps of $7.97, down 48.7% from 2021; and adjusted diluted eps of $9.95, down 30.1% from 2021 full year base business revenues of $8.43 billion, up 5.1% from 2021 full year covid-19 testing revenues of $1.45 billion, down 47.5% from 2021 full year 2023 reported diluted eps expected to be between $7.61 and $8.21; and adjusted diluted eps expected to be between $8.40 and $9.00 secaucus, n.j. , feb. 2, 2023 /prnewswire/ -- quest diagnostics incorporated (nyse: dgx), the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended december 31, 2022.
DGX Ratings Summary
DGX Quant Ranking